Felix Capanni

Prof. Dr. Felix Capanni

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CGCarolin Golla
Carolin Golla
MBMayas Bilal
Mayas Bilal
ADAnnika Dwucet
Annika Dwucet
NBNicolas Bader
Nicolas Bader
JAJenson Anthonymuthu
Jenson Anthonymuthu
Georg Karpel-MasslerGeorg Karpel-Massler
Georg Karpel-Massler
The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. Pre-clinical testing of a microcontroller-based device emitting light of 405 nm wavelength in combination with exposure to 5-ALA (PDT) and the Bcl-2/Bcl-xL inhibitor ABT-263 (navitoclax) was performed in human established and primary cultured glioblastoma cells as well as glioma stem-like cells. We applied cell count analyses to assess cellular proliferation and Annexin V/PI staining to examine pro-apoptotic effects. Western blot analyses and specific knockdown experiments using siRNA were used to examine molecular mechanisms of action. Bcl-2/Bcl-xL inhibition synergistically enhanced apoptosis in combination with PDT. This effect was caspase-dependent. On the molecular level, PDT caused an increased Noxa/Mcl-1 ratio, which was even more pronounced when combined with ABT-263 in a Usp9X-independent manner. Our data showed that Bcl-2/Bcl-xL inhibition increases the response of glioblastoma cells toward photodynamic therapy. This effect can be partly attributed to cytotoxicity and is likely related to a pro-apoptotic shift because of an increased Noxa/Mcl-1 ratio. The results of this study warrant further investigation.

21 November 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
RKRICHARD E. KAST
RICHARD E. KAST
AKAnton P. Kast
Anton P. Kast
JAJuergen Arnhold
Juergen Arnhold
FCFelix Capanni
Felix Capanni
Laura Natalia Milla SanabriaLaura Natalia Milla Sanabria
Laura Natalia Milla Sanabria
EJErasmo Barros da Silva Jr
Erasmo Barros da Silva Jr
This paper presents the basis for LoGlo PDT, a new treatment for glioblastoma. Glioblastoma is currently treated with maximal safe resection, temozolomide, and ionizing irradiation. Mortality in 2024 remains over 80% within several years from diagnosis. Oral 5-aminolevulinic acid (5-ALA) is an FDA/EMA approved drug that is selectively taken up by malignant cells, including by glioblastoma. In photodynamic treatment of glioblastoma, intense intraoperative light causes glioblastoma tissue that has taken up 5-ALA to generate cytotoxic reactive oxygen species. The requirement for intense light flux has restricted photodynamic treatment to a single one-hour intraoperative session. We analyze here published data showing that external light, illuminating the entire intact scalp, can attain low μW/cm2 flux several cm into intact brain that would be sufficient to mediate 5-ALA photodynamic treatment of glioblastoma if the light and 5-ALA are delivered continuously over 24 h. At the core of LoGlo PDT regimen is the dataset showing that, for a given fluence, as the duration of PDT light delivery goes down, light intensity (flux) delivered must go up to achieve the same glioblastoma cell cytotoxicity as would a weaker light (lower flux) delivered over a longer time. Thus, a repetitive, noninvasive PDT of glioblastoma using an external light source may be possible. We analyze 5-ALA cellular physiology to show that three non-oncology drugs, ciprofloxacin, deferiprone, and telmisartan, can be repurposed to increase light energy capture after 5-ALA, thereby increasing photodynamic treatment’s glioblastoma cell cytotoxicity. The LoGlo PDT approach uses both drug augmentation and prolonged ultra-low noninvasive transcranial light delivery for a repetitive, noninvasive 5-ALA photodynamic treatment of glioblastoma.
1

2 December 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NBNicolas Bader
Nicolas Bader
AHAnnika Hajosch
Annika Hajosch
CPChristian Peschmann
Christian Peschmann
KSKathrin Stucke-Straub
Kathrin Stucke-Straub
CWChristian Rainer Wirtz
Christian Rainer Wirtz
Georg Karpel-MasslerGeorg Karpel-Massler
Georg Karpel-Massler
Background/Objectives: Recurrence of glioblastoma (GBM) mostly occurs in close vicinity to the resection cavity. Therefore, our group has previously designed an implant to locally apply repetitive photodynamic therapy to mitigate tumor recurrence. The penetration depths of different wavelengths in brain tissue were exhaustively studied before. However, the PDT-induced biological effects of 5-ALA-based PDT against GBM cells at different depths have not been evaluated yet. Methods: Therefore, a synthetic brain substitute material of 1–10 mm thickness and with optical properties comparable to the white or gray matter of pig brain was developed. Tumor cell viability was assessed in spheroids from six GBM cell lines using disks of varying thickness prepared from pig brain substitute material to mimic in vivo radiation attenuation. Results: Using an artificial brain tissue optical model based on material science, we have established a relationship between the PDT-induced effect of our PDT implant and the distance of migrating GBM cells from the resection cavity wall. Conclusions: This model may be helpful to aid optimization of the irradiation doses and fractionation required to attain the maximal therapeutic effect by long-term PDT applications.

15 June 2026 in Physical Sciences Forum
Verified
Conference Paper
Open access
PDF file
MHMartin Hessling
Martin Hessling
BSBen Sicks
Ben Sicks
KLKlea Lila
Klea Lila
FCFelix Capanni
Felix Capanni
VFVinzent Forstmeier
Vinzent Forstmeier
Introduction: Biofilms are communities of microorganisms on wet or moist surfaces that are difficult to remove and can repeatedly release microorganisms. This causes significant problems in many areas, such as food technology and medicine, as biofilms can cause fatal infections in patients. One approach that has not yet been extensively researched is to prevent biofilm formation on surfaces by irradiating them with visible blue or violet light, which is known for its antimicrobial effect on planktonic bacteria. Methods: Various bacterial suspensions (Bacillus subtilis, Pseudomonas stutzeri, Streptococcus cristatus and Pseudomonas syringae) were placed in 24-well MTPs (microtiter plates) and irradiated with violet or blue light for up to 6 days. During this time, they were shaken at room temperature at a frequency of 100 rpm. The irradiation intensities were 0, 10 or 20 mW/cm2. After each day, the bacterial suspension was aspirated and the biofilm at the bottom of the well was assessed by absorption measurement and microscopy images. Results: Besides B. subtilis, thin biofilms were found on all well bottoms after 24 h, even on the irradiated microtiter plates. In general, however, the biofilm absorption/scattering was lower on the irradiated MTPs than on the non-irradiated ones. For B. subtilis, irradiation prevented biofilm formation during the observation period. Surprisingly, in most experiments, blue light had a stronger effect than violet light, which does not correspond to the experiences with planktonic bacteria. Conclusion: Violet and blue light exhibits a positive effect on suppressing the formation of new biofilm, but the applied maximum irradiance of 20 mW/cm2 was unable to prevent the formation of new biofilm for most of the examined bacteria. Further investigations with higher irradiance levels are necessary to determine whether it is possible to inhibit the formation of new biofilm altogether.